The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes

Access Activity

Overview / Abstract:

John Anderson, MD, and Vivian Fonseca, MD, provide their clinical insights into the rapidly evolving use of combined basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for the treatment of patients with type 2 diabetes mellitus (T2DM).
• Unmet needs
• Experience with basal insulin/GLP-1RA
• FRC basal insulin/GLP-1RAs
• Insulin degludec/liraglutide (DUAL)
• Insulin glargine/lixisenatide (LixiLan-L, -O)
• Using FRC basal insulin/GLP-1RAs
• Case studies


Oct 04, 2019


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME



Credits / Hours

1.5 ceu



Presenters / Authors / Faculty

John E. Anderson, MD
Frist Clinic
Nashville, Tennessee

Vivian A. Fonseca, MD
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Activity Specialities / Related Topics

Diabetes, Endocrinology, Primary Care

Sponsors / Supporters / Grant Providers

This activity is supported by an educational grant from Novo Nordisk Inc.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Basal insulin Insulin degludec/liraglutide Insulin glargine/lixisenatide GLP-1RA LixiLan-L Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.